Summary: Primary Progressive Multiple Sclerosis Study

A multinational, multicenter study to evaluate the effectiveness, tolerability, and safety of glatiramer acetate for injection in Primary Progressive Multiple Sclerosis patients.

Patient Inclusion Criteria
 

• Male or female patients between 30 and 65 years of age
• Patients must have had progressive neurologic symptoms for at least 6 months that lead the study doctor to conclude the patient has Primary Progressive Multiple Sclerosis (PPMS)
• No history of prior attacks of neurological disease

• Evaluated and ruled out other known significant systemic medical disease which may interfere with a diagnosis of PPMS
• Must not have a low white blood cell count
• Must not be using any interferon, immunosuppressive or immunomodulating drugs, steroids, or other investigational drugs in the last 3 months
• No other known life-threatening, significant, or uncontrolled medical illnesses
• Must never have used glatiramer acetate

Nicole Boo, Neurology

University of Kansas Medical Center
3901 Rainbow Boulevard
Kansas City, KS 66160
Telephone: 913-588-3968
Email: NBOO@kumc.edu